ARCHIVES

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

Accelerated Approval Will No Longer Block Competitors, FDA Commissioner Says

June 6, 2003

Phase III Trial: Panobinostat Increases PFS by Four Months

September 26, 2014

NCI Selects 15 Awardees to Operate the Cancer Information Service.

January 7, 2005

DCBD Concepts Approved

November 8, 1985

Kennedy Agrees To Drop Dollar Limit In New Cancer Bill

January 11, 1980

House Members Urge FDA to Review Fast Track Policies

July 5, 2002